SUMMARY The mean survival period in a series of 216 multiple sclerosis deaths, which formed part of a large prevalence sample observed in the Grampian region of Scotland, was 24 5 years, with an insignificant difference between females (25-7 years) and males (23.5 years). A third of the patients survived for over 30 years after onset. The age at death ranged between 25-80 years, with majority of the deaths occurring in the seventh decade (37%). On comparing life expectancy with the Scottish general population using life tables, only a slight reduction in the short-term (less than 10 years from onset) survival was noted in all age groups, with the exception of those with onset over the age of 50 years. The long-term life expectancy was however markedly reduced in all age groups compared with the controls. The survival period could be accurately predicted from the degree of disability at a point in time, and could be correlated with a number of clinical features, the most important of which was the age at onset. Eighty five per cent of those with onset of multiple sclerosis over the age of 50 years died within 20 years. Patients with a cerebellar disturbance at onset survived the shortest, and those with a brainstem lesion or retrobulbar neuritis the longest; those with a pyramidal dysfunction had an intermediate prognosis. Other parameters which could be correlated with the survival were: the timing and frequency of occurrence of psychiatric and urinary symptoms, interval between onset and first relapse and the course of the disease. As expected, most patients (89%) were significantly disabled (unable to walk) prior to death, only a minority, however, had become so within 10 years of the onset (10%). Sixty two per cent of the patients died of complications of multiple sclerosis. No unusual excess of any disease was noted amongst other causes. As expected, the majority of patients (55%) had bronchopneumonia as the terminal event, 11% had septicaemia, 15% had myocardial infarction and 4% had documented pulmonary embolism. This is the largest series of its kind where prognosis, judged by survival period, has been assessed amongst all multiple sclerosis patients derived from a prevalence sample and observed till death.
524 information based on a sample derived from a prevalence source, and only the Danish study12 encompassed a sufficiently large patient sample.
A number of clinical features, particularly those at onset of the disease have been shown to influence the survival period;6 11 22 of these only one series, however, was derived from a prevalence source. 22 Except in the series from Israel23 in most others where the cause of death in multiple sclerosis patients was analysed, a degree of selection was involved.68 21 23-25 Some have specifically attempted to assess the frequency of malignant diseases aongst multiple sclerosis patients9 13 [25] [26] [27] and all except one26 found no undue excess: in the series of Zimmermann and Netsky26 no comparison with a control population was made.
In the north east of Scotland, a large sample of multiple sclerosis patients (1055) has been closely observed for over a decade as part of an ongoing epidemiological investigation.2830 In this sample 216 deaths occurred between 1970-80; these represented all multiple sclerosis deaths in the region during that period. An attempt to answer a number of unsettled questions in the literature has been made. The period of survival for this unselected group was analysed and compared with age matched general population. Factors influencing the period of survival were analysed as well, and the causes of death were evaluated in detail.
Method
The Grampian region of Scotland was demarcated as a separate region in 1974 (fig 1) . Three epidemiological surveys for multiple sclerosis have been carried out there since 1970.28-3-A register for all multiple sclerosis patients was set up after the 1970 survey. All patients identified between 1970 and 1981 were periodically "flagged" with the central registrar office in Edinburgh. This facilitated automatic retrieval of death certificates of all multiple sclerosis patients. Between 1970 and there were 216 deaths. Almost all these patients had been seen on a number of occasions by a neurologist. The case notes of all these 216 deaths were re-analysed, and a number of details were recorded on a mainframe computer.
Factors such as sex, age at onset, initial symptoms, frequency and timing of occurrence of significant psychiatric and urinary symptoms and course of the disease were correlated with the length of survival calculated from the year of the first symptom to the year of death.
The age at onset was known in the case of 200, and age at death for all the 216 patients. The initial symptoms were grouped into:
(a) (1) Survival at 10 years after onset was only minimally reduced for all patients except those with onset over the age of 50 years, in whom it was reduced by 44% for the males and 22% for the females compared to age matched controls ( Tables (table 2 ). The probability of survival at 10 years for a male patient aged 25 expected figure of 98%; the respective figures for females were 86% and 98%. The probability of such a patient surviving till the age of 65 years was only 4% in males and 6% in females; the comparative figures for a person from the age matched general population was 77% in males and 84% in females. (Grades V-VI) only 28% were alive at 10 years.
CORRELATION BETWEEN PERIOD OF SURVIVAL AND VARIOUS CLINICAL FEATURES
Age at onset and sex by survival The survival period was inversely linked to the age at onset (table 3) . This relationship between the two was highly significant on independent or combined analysis for either sex (p < 0-001). Females on the whole survived slightly longer (except those with onset between the ages of 30-39 years); the differences between males and females in different age groups however were statistically not significant. Pattern Survival by course of the disease Those with a relapsing remitting disease survived the longest, followed by those with initially relapsing and later progressive disease. Patients who had a steadily increasing progressive disability from the start had the shortest survival (p < 0 001) (table 7) .
The cerebrospinalfluid was analysed in two thirds of the cases. Changes in any of the CSF parameters had no relationship with the survival period.
CAUSE OF DEATH
As shown in Survival pattern and cause of death in patients with multiple sclerosis cerebral or peripheral vessels, and 5% from other miscellaneous conditions. The cause of death was unknown for two patients. The degree of disability nearer the time of death and the individual causes are listed in table 8. Out of the various malignancies, bronchogenic carcinoma occurred most frequently; this was in keeping with the general trend in the west. Frequency of diseases in multiple sclerosis patients and those in the general population could not be compared owing to lack of precise incidence figures for most diseases in the community; no undue excess of any particular disease was however observed amongst the patients. Out of the 132 patients who died due to complications of multiple sclerosis, in the case of 31 one additional cause, and in nine two additional causes were also responsible for early death.
The terminal event was known in 151 patients; 55% died of bronchopneumonia, 1 % had confirmed septicaemia, 15% had myocardial infarction, 4% had pulmonary embolism diagnosed clinically, and the remaining 15% died of other miscellaneous conditions such as gastrointestinal bleeding (1), gangrene of the legs (1), pneumothorax (1), inhalation asphyxia (5) etc. The rather low incidence of pulmonary embolism was certainly an underestimate, as the majority of patients with terminal respiratory illness did not have investigations such as ventilation perfusion scan and were thought as having bronchopneumonia only on the grounds of clinical and plain radiological findings.
The necropsy rate was rather low (16%), similar to the general trend in western centres. The clinical diagnosis of multiple sclerosis was confirmed in all the 35 cases undergoing necropsy.
Discussion
In most studies published prior to the sixties, survival period after onset of multiple sclerosis has been A more realistic figure, as noted presently, and also With few exceptions6 11 32 34 35 clinical features influencing the prognosis have been correlated in most studies with the disability at a point in time amongst the living, rather than with the total period of survival amongst those observed till death. During the present investigation both groups were studied separately, and the results for those living in the region in December 1980 will be published separately.
In the present study no significant difference in the life expectancy was noted between the sexes; this is in general agreement with findings in most other centres.
As noted by others22 23 33 
